Results 271 to 280 of about 3,910,323 (355)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Effective components of Coptidis Rhizoma and Cinnamomi Cortex in the treatment of renal cell carcinoma and their mechanism of action. [PDF]

Medicine (Baltimore)
Duan D, Wang J, Chen M, Tan L, Song L.
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. [PDF]

Cancer Discov
Yuan L, Ji W, Dwyer BG, Lu J, Bian J, Colombo GM, Martinez MJ, Fernandez D, Phillips NA, Tang MT, Zhou CW, Quispe Calla NE, Guzman Huancas C, Eckart M, Tran J, Jones HM, Qiu T, Doench JG, Rees MG, Roth JA, Cameron MD, Charville GW, Kuo CJ, Dixon SJ, Zhang T, Hinshaw SM, Gray NS, Corsello SM.   +27 more
europepmc   +1 more source

Politics of History: Creators, Tools, Mechanisms of Action – the Case Study of Poland

, 2017
Katarzyna Kącka
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate. [PDF]

Elife
Li H, Ji S, Ariefta NR, Galon EMS, El-Sayed SAES, Do T, Jia L, Sakaguchi M, Asada M, Nishikawa Y, Qin X, Liu M, Xuan X.   +12 more
europepmc   +1 more source

Figure 3 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

James P.B. O’Connor, Victoria Tessyman, Ross A. Little, Muhammad Babur, Duncan Forster, Ayşe Latif, Susan Cheung, Grazyna Lipowska‐Bhalla, Geoff S. Higgins, Marie‐Claude Asselin, Geoff J.M. Parker, Kaye J. Williams   +11 more
openalex   +1 more source

MECHANISMS OF HORMONE ACTION

British Journal of Anaesthesia, 1981
openaire   +2 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source